UroGen Pharma URGN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $50.96M+34.7% | $37.84M+37.7% | $27.48M+13.5% | $24.22M+19.6% | $20.25M-17.5% | ||
| -$23.57M+10.6% | -$26.36M+20.9% | -$33.35M+33.2% | -$49.94M-13.9% | -$43.84M-16.9% | ||
| -46.3%+23.4pp | -69.7%+51.7pp | -121.3%+84.9pp | -206.2%+10.2pp | -216.5%-63.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are UroGen Pharma's profit margins?
- Gross margin is 89.7% and operating margin is -329.7%, with a -94.8% net margin.
- Where does UroGen Pharma's income statement data come from?
- Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.